-

$undefined

N/A

(N/A)

Precigen NASDAQ:PGEN Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The Company's technologies enable to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

Location: 20374 Seneca Meadows Parkway, Maryland, 20876, US | Website: precigen.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

536.5M

Cash

28.63M

Avg Qtr Burn

-18.92M

Short % of Float

12.93%

Insider Ownership

9.93%

Institutional Own.

66.37%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PRGN-2012 AdenoVerse™ (zopapogene imadenovec) Details Recurrent respiratory papillomatosis, Cancer	BLA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRGN-2009 OTS AdenoVerse™ +/- Pembrolizumab Details Cancer, Solid tumor/s, Squamous cancers	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRGN-2009 AdenoVerse™ + Pembrolizumab Details Cancer, Cervical cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRGN-3005 UltraCAR-T® Details Cancer, Ovarian cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRGN-3006 UltraCAR-T® Details Cancer, Acute myeloid leukemia	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRGN-3007 UltraCAR-T® Details Cancer, Blood cancer, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AG019 ActoBiotics™ Details Type 1 diabetes, Diabetes	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.